ストックスクリーナーアプリを入手
24.27
7.06%
1.60
アフターアワーズ：
24.27
前日終値:
$22.67
開ける：
$22.67
24時間の取引高:
552.58K
Relative Volume:
0.63
時価総額：
$1.46B
収益：
$13.05M
当期純損益:
$-60.54M
株価収益率:
-20.92
EPS:
-1.16
ネットキャッシュフロー:
$-37.82M
1週間 パフォーマンス:
-4.82%
1か月 パフォーマンス:
-3.50%
6か月 パフォーマンス:
-34.01%
1年 パフォーマンス:
-33.69%
1日の値動き範囲:
$22.67
$24.39
1週間の範囲:
$21.97
$25.41
52週間の値動き範囲:
$21.97
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
名前
Janux Therapeutics Inc
セクター
電話
(858) 751-4493
住所
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
JANX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
24.27 | 1.37B | 13.05M | -60.54M | -37.82M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-11 | 開始されました | Raymond James | Outperform |
| 2024-12-03 | 繰り返されました | BTIG Research | Buy |
| 2024-12-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-11-22 | 開始されました | Leerink Partners | Outperform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-09-06 | 開始されました | Stifel | Buy |
| 2024-05-30 | 開始されました | Scotiabank | Sector Perform |
| 2024-03-21 | 開始されました | BTIG Research | Buy |
| 2024-03-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-04-06 | 開始されました | Wedbush | Outperform |
| 2022-11-14 | 開始されました | William Blair | Outperform |
すべてを表示
Janux Therapeutics Inc (JANX) 最新ニュース
Promising Pipeline and Financial Stability Support Buy Rating for Janux Therapeutics Inc - TipRanks
Promising Developments and Strategic Expansion at Janux Therapeutics: Analyst Sets $70 Price Target - TipRanks
Janux Therapeutics Earns Buy Rating Amid Promising Pipeline and Strong Financial Position. - AInvest
RSI Crosses Above 30 for Janux Therapeutics Inc. — Reversal in SightTarget Return Focused Trade Insights Shared - metal.it
Buy Rating for Janux Therapeutics Driven by Promising Pipeline and Strong Financial Position - TipRanks
Janux Therapeutics 2024 Q3 Earnings Widening Losses Amidst Revenue Decline - AInvest
Janux Therapeutics stock hits 52-week low at 22.25 USD - Investing.com
Janux Therapeutics stock hits 52-week low at 22.25 USD By Investing.com - Investing.com Nigeria
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $59 to $100 - 富途牛牛
Janux (JANX) R&D Soars Revenue Misses - AOL.com
Janux Therapeutics Reports Q2 2025 Financial Results - TipRanks
Janux Therapeutics 2024 Q3 Earnings Deepening Losses Amid Pipeline Progress - AInvest
Janux Therapeutics Inc. Receives Buy Rating for Promising Pipeline and Financial Stability - AInvest
Optimistic Outlook for Janux Therapeutics: Strong Cash Position and Promising ‘007 Program Drive Buy Rating - TipRanks
Optimistic Buy Rating for Janux Therapeutics Inc. Driven by Promising R&D, Strong Cash Position, and Strategic Expansion - TipRanks
Janux Therapeutics reports Q2 EPS (55c), consensus (47c) - TipRanks
Janux Therapeutics Reports Q2 FY25 Financial Results, $996mln Cash, Milestone Payment from Merck. - AInvest
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - Business Wire
Janux Therapeutics reaches clinical milestone in Merck TRACTr collaboration - TipRanks
Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck - Business Wire
Is Janux Therapeutics Inc. a growth stock or a value stockSuperior return velocity - Jammu Links News
What analysts say about Janux Therapeutics Inc. stockTrack top-performing stocks in real-time - Jammu Links News
What are the latest earnings results for Janux Therapeutics Inc.Build wealth faster with consistent investment plans - Jammu Links News
Should I hold or sell Janux Therapeutics Inc. stock in 2025Free Market Dynamics Reports - Jammu Links News
What drives Janux Therapeutics Inc. stock priceExplosive trading growth - Jammu Links News
Janux Therapeutics Inc. Stock Analysis and ForecastAchieve breakthrough gains with expert advice - Jammu Links News
How does Janux Therapeutics Inc. generate profit in a changing economyMaximize your gains with professional insights - Jammu Links News
Is Janux Therapeutics Inc. stock overvalued or undervaluedMaximize gains with data-driven stock picks - Jammu Links News
What makes Janux Therapeutics Inc. stock price move sharplyAccess powerful market insights for free - Jammu Links News
What are analysts’ price targets for Janux Therapeutics Inc. in the next 12 monthsUnlock your portfolio’s hidden potential - Jammu Links News
How does Janux Therapeutics Inc. compare to its industry peersAccelerated financial growth - Jammu Links News
Can Janux Therapeutics Inc. Regain Momentum After BreakdownReal Trader Watchlist of Hot Stocks Released - metal.it
Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash - Seeking Alpha
Optimistic Buy Rating for Janux Therapeutics Driven by Strategic Pipeline and Diversification - TipRanks
Why Janux Therapeutics Inc. stock attracts strong analyst attentionTriple Return Setup With Risk Control Explained - metal.it
Janux Therapeutics Receives Buy Rating from Leerink Partners Analyst Jeffrey La Rosa - AInvest
Why did JANX's operating expenses surge in Q3 2024? - AInvest
Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Janux Therapeutics Inc (JANX) - The Globe and Mail
Analysts Praise Ionis Pharmaceuticals and Janux Therapeutics for Bright Healthcare Futures - AInvest
JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $90 - 富途牛牛
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
Combining machine learning predictions for Janux Therapeutics Inc. Yield Curve Outlook and Long-Term Implication Summary - metal.it
What is the dividend policy of Janux Therapeutics Inc. stockSuperior stock selection - Jammu Links News
Janux Therapeutics Inc (JANX) 財務データ
収益
当期純利益
現金流量
EPS
Janux Therapeutics Inc (JANX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Meyer Andrew Hollman | Chief Business Officer |
May 01 '25 |
Sale |
32.03 |
3,333 |
106,745 |
82,139 |
0.91%
3.06%
大文字化:
|
ボリューム (24 時間):